ChemistrySelect,
Journal Year:
2024,
Volume and Issue:
9(37)
Published: Oct. 1, 2024
Abstract
Lung
cancer
is
now
the
leading
cause
of
cancer‐related
mortality,
eclipsing
all
other
forms,
and
lung
malignancies,
non‐small
cell
(NSCLC)
makes
up
around
85%.
Recently,
use
vectors
in
gene
therapy
besides
chemotherapy
to
treat
malignancies
brought
on
by
mutations
has
gained
prominence.
Therapeutic
molecule
inhalation
a
direct
approach
lung‐targeted
medication
delivery
with
low
nonspecific
toxicity
limited
drug
exposure.
Treatment
for
immunotherapy
can
be
aided
inhalable
nanomedicine
through
advanced
mechanisms.
Viral
nonviral
vectors,
such
as
lipid‐based
nanoparticles,
polymeric
inorganic
have
drawn
lot
interest
their
ability
increase
effects
decrease
side
effects.
Nanocarriers
significant
impact
targeted
delivery,
bioavailability,
stability,
residence
target
areas.
The
inhaled
pulmonary
approach,
when
combined
nanomedicine,
will
offer
noninvasive
successful
way
taking
physiological
properties
lung.
authors
majorly
used
data
from
PubMed
Google
Scholar
obtain
relevant
information
required
article.
In
general,
this
review
concentrates
usage
various
nanocarriers,
which
might
serve
an
inspiration
creation
deployment
more
potent
genetic
treatment
cancer.
Cell,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Intranasal
administration
through
the
olfactory
epithelium
(OE)
presents
a
direct
pathway
for
brain-targeted
therapeutic
delivery,
although
its
feasibility
is
hampered
by
anatomical
and
absorptive
limitations
of
OE.
In
this
study,
we
identified
Lactobacillus
plantarum
WCFS1
(Lp),
commensal
strain
with
natural
affinity
OE
engineered
it
to
function
as
vector
cerebral
drug
delivery.
Upon
intranasal
administration,
Lp
released
specific
payload
molecules
within
OE,
subsequent
transport
accumulation
in
brain.
The
efficacy
was
further
validated
recombinant
production
secretion
appetite-regulating
hormones.
When
administered
intranasally
murine
model
obesity
prevention,
significantly
alleviated
obesity-related
symptoms.
This
evidenced
decreased
appetite,
reduced
body
weight
gain,
improved
glucose
metabolism
fat
mass
deposition.
Our
study
demonstrates
capability
an
delivery
vehicle,
emphasizing
potential
applications.
Journal of Bio-X Research,
Journal Year:
2024,
Volume and Issue:
7
Published: Jan. 1, 2024
Artificial
intelligence
(AI)
and
machine
learning
(ML)
are
revolutionizing
the
pharmaceutical
industry,
particularly
in
drug
development
delivery.
These
technologies
enable
precision
medicine
by
analyzing
extensive
datasets
to
optimize
formulations
predict
patient
responses.
AI-driven
models
enhance
nanoparticle-based
carriers,
improving
their
stability,
bioavailability,
targeting
accuracy.
ML
also
facilitates
real-time
monitoring
adaptive
control
of
release,
ensuring
better
therapeutic
outcomes.
This
review
explores
integration
AI
delivery,
highlighting
potential
accelerate
development,
reduce
costs,
advance
personalized
medicine.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(10), P. 1322 - 1322
Published: Oct. 11, 2024
The
application
of
serum
albumin
in
various
types
formulations
has
emerged
as
a
valuable
option
biomedical
research,
especially
the
field
nasal
drug
delivery
systems.
A
albumin-based
carrier
system
been
employed
due
to
several
benefits,
such
enhancing
solubility
and
stability,
generating
desired
controlled
release
profile,
developing
favorable
properties
with
respect
challenges
conditions,
which,
this
case,
involves
hindering
rapid
elimination
mucociliary
clearance.
Accordingly,
considering
important
role
albumin,
in-depth
knowledge
related
its
utilization
preparing
formulation
is
highly
encouraged.
This
review
aimed
explore
potential
fabricating
crucial
functionality
regarding
binding
interaction
mucin,
which
significantly
determines
successful
administration
formulations.
Drug Delivery,
Journal Year:
2025,
Volume and Issue:
32(1)
Published: Feb. 3, 2025
The
present
study
aimed
to
prepare
and
optimize
lamotrigine-loaded
bovine
serum
albumin
nanoparticles
(LAM-NP)
using
the
Quality
by
Design
(QbD)
approach
investigate
both
in
vitro
ex
vivo
effects
of
different
cross-linking
agents
glutaraldehyde
(GLUT),
glucose
(GLUC)
1-(3-dimethylaminutesopropyl)-3-ethylcarbodiimide
hydrochloride
(EDC)
on
intranasal
applicability.
Cross-linked
LAM-NP
from
EDC
(NP-EDC-1)
showed
lowest
Z-average
value
(163.7
±
1.9
nm)
drug
encapsulation
efficacy
(EE%)
97.31
0.17%.
release
GLUC
cross-linked
(NP-GLUC-9),
(NP-GLUT-2),
NP-EDC-1
at
blood
circulation
conditions
was
higher
than
initial
LAM.
results
blood-brain
barrier
parallel
artificial
membrane
permeability
assay
(BBB-PAMPA)
an
increase
LAM
through
BBB
with
NP-GLUC-9
flux
all
selected
formulations.
that
diffusion
formulations
human
nasal
mucosa
case
cytotoxicity
indicated
BSA-NP
reduced
toxicity,
9
mM
1
mg
could
be
alternative
avoid
GLUT
2%
v/v
toxicity.
Furthermore,
Caco-2
cells
epithelial
transport/absorption
improved
BSA-NPs.
use
may
a
promising
enhance
solubility,
decrease
frequency
dosing
adverse
Expert Opinion on Drug Delivery,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 20, 2025
Introduction
Traditional
administration
routes
have
limitations
including
first-pass
metabolism
and
gastrointestinal
degradation
for
sensitive
drugs
(oral)
pain
associated
with
parenteral
injections,
which
also
require
trained
personnel
refrigeration,
making
them
expensive.
This
has
increased
interest
in
alternative
routes,
mucosal
surfaces
being
of
high
priority.
